Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

This bill increases funding and expands the scope of federal efforts to address sickle cell disease. It boosts annual funding for research and treatment programs from $4.455 million (2019-2023) to $8.205 million (2025-2029) and updates language to specifically include "prevention and treatment of complications" alongside disease treatment. The bill also modifies grant procedures to allow more flexible funding mechanisms for organizations working on sickle cell disease and related heritable blood disorders. It directly affects federal health agencies, researchers, and healthcare providers serving patients with sickle cell disease, focusing on concrete policy changes in funding and program scope.